

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 04, 2024, 10:29 PM
Patient ID / UHID : 8053314/RCL7248013	Barcode No : HY569760
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Whole blood EDTA	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Cancer Screening Package Advance - Male

Complete Blood Count (CBC)

RBC Parameters			
Hemoglobin <i>Spectrophotometry</i>	11.5	g/dL	13.0 - 17.0
RBC Count <i>Electrical impedance</i>	4.8	10 ⁶ /μl	4.5 - 5.5
PCV <i>Calculated</i>	34.9	%	40 - 50
MCV <i>Calculated</i>	73.3	fl	83 - 101
MCH <i>Calculated</i>	24.1	pg	27 - 32
MCHC <i>Calculated</i>	32.9	g/dL	31.5 - 34.5
RDW (CV) <i>Calculated</i>	14.3	%	11.6 - 14.0
RDW-SD <i>Calculated</i>	36	fl	35.1 - 43.9
WBC Parameters			
TLC <i>Electrical impedance and microscopy</i>	10.4	10 ³ /μl	4 - 10
Differential Leucocyte Count			
Neutrophils <i>Flow-cytometry DHSS</i>	57.2	%	40-80
Lymphocytes <i>Flow-cytometry DHSS</i>	30.2	%	20-40
Monocytes <i>Flow-cytometry DHSS</i>	9	%	2-10
Eosinophils <i>Flow-cytometry DHSS</i>	3.6	%	1-6
Basophils <i>Flow-cytometry DHSS</i>	0	%	<2
Absolute Leukocyte Counts <i>Calculated</i>			
Neutrophils.	5.95	10 ³ /μl	2 - 7
Lymphocytes. <i>Calculated</i>	3.14	10 ³ /μl	1 - 3
Monocytes. <i>Calculated</i>	0.94	10 ³ /μl	0.2 - 1.0
Eosinophils. <i>Calculated</i>	0.37	10 ³ /μl	0.02 - 0.5
Basophils.	0	10 ³ /μl	0.02 - 0.5

Dr. Islam Barkatullah Khan

Dr. Islam Barkatullah Khan
MD (Pathology)
Consultant Pathologist



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY		Sample Collected : Apr 26, 2024, 01:00 PM	
DOB/Age/Gender : 23 Y/Male		Report Date : May 04, 2024, 10:29 PM	
Patient ID / UHID : 8053314/RCL7248013		Barcode No : HY569760	
Referred By : Dr. Dr. X		Report Status : Final Report	
Sample Type : Whole blood EDTA			
Test Description	Value(s)	Unit(s)	Reference Range
<i>Calculated</i>			
Platelet Parameters			
Platelet Count <i>Electrical impedance and microscopy</i>	163	10 ³ /μl	150 - 410
Mean Platelet Volume (MPV) <i>Calculated</i>	11.8	fL	9.3 - 12.1
PCT <i>Calculated</i>	0.2	%	0.17 - 0.32
PDW <i>Calculated</i>	29.8	fL	8.3 - 25.0
P-LCR <i>Calculated</i>	50.4	%	18 - 50
P-LCC <i>Calculated</i>	82	%	44 - 140
Mentzer Index <i>Calculated</i>	15.27	%	> 13
Interpretation: CBC provides information about red cells, white cells and platelets. Results are useful in the diagnosis of anemia, infections, leukemias, clotting disorders and many other medical conditions.			

Dr. Islam Barkatullah Khan

Dr. Islam Barkatullah Khan
MD (Pathology)
Consultant Pathologist



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 04, 2024, 03:06 PM
Patient ID / UHID : 8053314/RCL7248013	Barcode No : ZC624441
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Serum	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

Carcinoembryonic Antigen (CEA)

CEA; CARCINO EMBRYONIC ANTIGEN, SERUM CMIA	2.8	ng/mL	<3.0
---	-----	-------	------

Interpretation:

REFERENCE GROUP	REFERENCE RANGE IN ng/mL
Non Smokers	<3.0
Smokers	<5.0

Note :

1. This test is not recommended for cancer screening in the general population.
2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy.
3. Patients with confirmed carcinoma may show normal pre-treatment CEA levels. Hence this assay, regardless of level, should not be interpreted as absolute evidence for presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.
4. Persistently elevated CEA levels are usually indicative of progressive malignant disease and poor therapeutic response.

Clinical Use

1. Monitoring patients with Colorectal, Gastrointestinal, Lung & Breast carcinoma
2. Diagnosis of occult metastatic disease and / or residual disease



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 04, 2024, 03:06 PM
Patient ID / UHID : 8053314/RCL7248013	Barcode No : ZC624441
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Serum	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

CA 19.9 (Pancreatic Cancer Marker)

CA 19.9 ;PANCREATIC CANCER MARKER, SERUM CMIA	12.3	U/mL	<37
--	------	------	-----

Interpretation:

Note :

- This test is not recommended to screen Pancreatic cancer in the general population.
- False negative/positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
- This assay, regardless of level, should not be interpreted as absolute evidence for the presence or absence of malignant disease. The assay value should be used in conjunction with findings from clinical evaluation and other diagnostic procedures.
- Persistently elevated CA 19-9 levels are usually indicative of progressive malignant disease and poor therapeutic response

Clinical Use :

- An aid in the management of Pancreatic cancer patients
- Monitor the course of disease and predict recurrence in patients with Pancreatic carcinoma

DISEASE	PERCENTAGE POSITIVITY OF CA 19.9
Pancreatic cancer	80
Hepatobiliary cancer	67
Gastric cancer	40-50
Hepatocellular cancer	30-50
Colorectal cancer	30
Breast cancer	15
Pancreatitis	10-20
Benign Gastrointestinal diseases	10-20



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

📞 928-909-0609

✉ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name : Mr MR.DUMMY	Sample Collected : Apr 26, 2024, 01:00 PM
DOB/Age/Gender : 23 Y/Male	Report Date : May 04, 2024, 03:06 PM
Patient ID / UHID : 8053314/RCL7248013	Barcode No : ZC624441
Referred By : Dr. Dr. X	Report Status : Final Report
Sample Type : Serum	

Test Description	Value(s)	Unit(s)	Reference Range
------------------	----------	---------	-----------------

PSA Profile

Prostate Specific Antigen, Total	2.3		
Prostate Specific Antigen, Free <i>CMIA</i>	0.32	ng/mL	0 - 0.5
%Free Prostate Specific Antigen, Ratio	13.91		

Interpretation:

Age Group (Years)	Probability of Malignancy		
	50-59	60-69	≥ 70
% fPSA ratio			
≤ 10	49.20%	57.50%	64.50%
11-18	26.90%	33.90%	40.80%
19-25	18.30%	23.90%	29.70%
> 25	9.10%	12.20%	15.80%

- Note**
- Free PSA values regardless of levels should not be interpreted as absolute evidence for the presence or absence of disease. All values should be correlated with clinical findings and results of other investigations
 - False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
 - Free PSA levels may appear consistently elevated / depressed due to the interference by heterophilic antibodies & nonspecific protein binding
 - Immediate Free PSA testing following digital rectal examination, ejaculation, prostatic massage, ultrasonography and needle biopsy of prostate is not recommended as they falsely elevate levels
 - Hormone therapy affects Free PSA expression

Clinical Use

- An aid in the early detection of Prostate cancer in males 50 years or older with Total PSA values between 4.0 and 10.0 ng/mL and nonsuspicious digital rectal examination.
- An aid in discriminating between Prostate cancer and Benign Prostatic disease. Free PSA level is not used alone, but is mostly useful when expressed in a ratio with Total PSA. Hence PSA profile (Total + Free PSA) is the recommended test. Patients with benign conditions have a higher proportion of Free PSA compared with Prostate cancer

*** End Of Report ***

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.



Dr. Dummy



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.